Skip to content
Screener

Operating Income at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$94.2M-95.0%
Arvinas logo
ArvinasARVN
-$63.8M-189%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$75.61M+10.6%
Vor Biopharma logo
Vor BiopharmaVOR
-$35.16M-5.6%
Biohaven logo
BiohavenBHVN
-$130.43M+41.1%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$15.55M-8.0%

Other financials

Income statement

See full
Revenue$9.0M-61.3%
Net income-$43.4M-253%
EPS (diluted)-$0.43-187%

Balance sheet

See full
Cash & equivalents$90.1M+29.8%
Total debt$38.0M-7.6%
Total equity$487.3M+81.8%
Total assets$691.2M+92.2%

Cash flow

See full
Operating cash flow-$44.1M-27.1%
CapEx$4.7M+179%
Free cash flow-$48.8M-34.1%

Valuation

See full
Market cap$1.33B+395%
Enterprise value$1.28B+432%
P/S46.2×+44.7×

Profitability

See full
Operating margin-633%
Net margin-560.8%
FCF margin-111.7%-125pp

Returns & leverage

See full
Return on equity-42.7%
Debt / equity0.1×-0.1×
Current ratio10.6×+3.4×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:09 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336711
(in thousands, except share and per share amounts)Three months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Research and development47,96430,65392,03362,843
General and administrative10,1348,09520,30916,798
Total operating expenses58,09838,748112,34279,641
(Loss) income from operations(49,130)(15,554)(99,164)28,482
Other income:
Interest income5,9163,06811,5076,507
Foreign currency exchange gain251,390171,563
Gain on disposal of property and equipment59

Item 1. Financial Statements

FAQ

What is Monte Rosa Therapeutics, Inc.'s operating income?
Monte Rosa Therapeutics, Inc. (GLUE) reported operating income of -$49.13M in Q2 2026.
How has Monte Rosa Therapeutics, Inc.'s operating income changed year-over-year?
Monte Rosa Therapeutics, Inc.'s operating income decreased by 215.9% year-over-year, from -$15.55M to -$49.13M.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s operating income?
Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s operating income has grown at a -9.4% compound annual growth rate (CAGR), from -$72.88M to -$54.21M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Monte Rosa Therapeutics, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude